CD40L
| Aliases: | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L |
|---|---|
| Other: | CD40 ligand|CD40 antigen ligand|CD40-L|T-B cell-activating molecule|T-cell antigen Gp39|TNF-related activation protein|tumor necrosis factor (ligand) superfamily member 5 |
The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome. [provided by RefSeq, Jul 2008]
PE-Cy5.5
| Common Laser: | 488-561 |
|---|---|
| Common Filter: | 695/40 |
| Excitation Peak: | 565 |
| Emission Peak: | 695 |
PE-Cyanine®5.5 (PE-Cy5.5) is a red-emitting tandem fluorophore that combines phycoerythrin (PE) and Cy5.5. The donor molecule, PE can be excited by the 488-nm blue, 532-nm green, or 561-nm yellow-green laser and and transfers energy to the acceptor molecule, Cy5.5. PE-Cy5.5 has an excitation peak at 496 nm and an emission peak at 695 nm.
Popular CD40L PE-Cy5.5 Antibodies
| Company / SKU |
Applications | Marker / Reactivity |
Host / Isotype / Clone |
Size / Price |
Details | |
|---|---|---|---|---|---|---|
|
Novus Biologicals NBP2-52678PECY55 |
FC | CD40L Human |
Rabbit IgG κ hu5c8 (Ruplizumab) |
0.1 ml $518 |
Details | |
|
Novus Biologicals NBP2-52678PECY55-100ul |
FC | CD40L Human |
Rabbit IgG κ hu5c8 (Ruplizumab) |
100 μl $479 |
Details | |
|
Novus Biologicals NBP2-75907PECY55-100ul |
FC | CD40L Human |
Human IgG1 κ hu5c8 (Ruplizumab) |
100 μl $449 |
Details | |
|
NBP2-75907PECY55 |
FC | CD40L Human |
Human IgG1 κ hu5c8 (Ruplizumab) |
100 μl $279 |
Details | |
|
Novus Biologicals NBP2-75907PECY55 |
FC | CD40L Human |
Human IgG1 κ hu5c8 (Ruplizumab) |
0.1 ml $518 |
Details | |
|
Novus Biologicals NBP2-62194PECY55 |
FC | CD40L Human,Primate |
Mouse IgG1 24-31 |
0.1 ml $388 |
Details | |
|
NBP2-52678PECY55 |
FC | CD40L Human |
Rabbit IgG κ hu5c8 (Ruplizumab) |
100 μl $279 |
Details | |
| Browse CD40L / PE-Cy5.5 antibodies. | ||||||
